The present pipeline of pharmaceutical products is increasingly complex and requires specialised facilities, equipment and operational expertise. Small molecule drugs account for nearly 90 percent of the therapeutics in the global pharma market. In 2017, the US FDA's Center for Drug Evaluation and Research approved 34 small molecule drugs. This represents an annual growth of nearly 56 percent, signifying the growing importance of contract manufacturing in the overall pharmaceutical industry.
展开▼
